23:57 , Jul 26, 2018 |  BC Innovations  |  Targets & Mechanisms

PureTech plumbs the brain

PureTech Health plc is backing a new way of thinking about Alzheimer’s disease that positions it primarily as a problem of poor drainage, building on the recent discovery of lymphatic vessels in the brain by...
22:27 , Jul 25, 2018 |  BC Extra  |  Preclinical News

Expanding brain lymphatics restores cognitive function

A Nature paper published Wednesday showed that enhancing the function of the brain’s lymphatic vessels can reverse age-related cognitive decline in mice and could be a strategy for treating Alzheimer’s disease. PureTech Health plc (Boston,...
17:57 , May 11, 2018 |  BC Week In Review  |  Financial News

MabSpace raises $40M series B

MabSpace Biosciences Co. Ltd. (Suzhou, China) raised $40 million in a series B round led by new investor Sequoia Capital China, with participation from new investor King Star Capital and existing investor Lilly Asia Ventures. MabSpace...
21:04 , May 10, 2018 |  BC Extra  |  Financial News

Chinese companies MabSpace and ICT announce series B rounds

MabSpace Biosciences Co. Ltd. (Suzhou, China) and Innovative Cellular Therapeutics Co. Ltd. (Shanghai, China) raised $40 million and RMB180 million ($28.3 million), respectively, in series B rounds. New investor Sequoia Capital China led MabSpace’s round with...
22:41 , Apr 24, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Animal models Mice with bone-specific overexpression of VEGF-C could be used to screen therapies to treat Gorham-Stout disease. Generation of the model involves crossing a mouse line, in which expression of a tetracycline transactivator cassette...
19:53 , Oct 12, 2017 |  BC Innovations  |  Translation in Brief

Opening doors for I-O

A Science Translational Medicine study has flipped the script for tumor lymphangiogenesis by turning VEGF-C, a hallmark of poor prognosis, into a biomarker and a target for successful responses to immunotherapies. Tumors that are surrounded by...
19:40 , Oct 3, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Serum levels of VEGF-C could help predict responses to immunotherapies in patients with solid tumors. In sera from 20 metastatic melanoma patients vaccinated with melan-A (MLANA; MART1) peptide and the toll-like receptor 9...
20:28 , Nov 23, 2016 |  BC Week In Review  |  Clinical News

OPT-302: Completed Ph I/IIa enrollment

Opthea completed enrollment of 31 patients in the dose-expansion Phase IIa portion of a single-blind, U.S. Phase I/IIa trial evaluating once-monthly 2 mg intravitreal OPT-302 as monotherapy or in combination with Lucentis ranibizumab for...
08:00 , Jan 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Vascular endothelial growth factor receptor 3 (FLT4; VEGFR-3); vascular endothelial growth factor C (VEGF-C)

Transplant INDICATION: Graft rejection Mouse studies suggest a form of VEGF-C that selectively activates FLT4 signaling could help prevent lung graft rejection. In mice that received lung transplants, allografts undergoing acute rejection had lower numbers of lymphatic...
07:00 , Jun 11, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Vascular endothelial growth factor C (VEGF-C)

Cardiovascular disease INDICATION: Myocardial infarction (MI) Mouse studies suggest VEGF-C or other lymphangiogenesis-stimulating agents could help treat MI. In a mouse model of surgically induced MI, cardiac expression of lymphangiogenic genes and growth of lymphatic vessels in...